Experimental drug axatilimab made available for one patient with chronic GVHD
NCT ID NCT05544032
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This program offers expanded access to the drug axatilimab for a single patient with chronic graft versus host disease (GVHD), a complication after a stem cell transplant. The patient receives intravenous doses every two weeks. Approval is needed from the company, an ethics committee, and the FDA.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axatilimab
What this could lead to
If it works, this could provide a treatment option for chronic GVHD when other therapies have failed.
What could go wrong
This is a single-patient program, not a full clinical trial. Results may not apply to others, and risks like infection or side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VS. HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••